Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Biotechnology

Healthcare
$8.44 +3.04%

+$0.26 today

Market cap
$547.12M
Beta
1.80
P/E (TTM)
-1.7
EPS (TTM)
-$5.11
52W Low $5.37High $17.58

Volume 2.36M

Average 1.24M

DNA Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Ginkgo Bioworks Holdings, Inc.NYSE: DNA

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization dips below year-ago levels

Q1 FY2026 depreciation & amortization of $12.8M fell 16.7% year over year, behind the +36.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 72.5% from the prior quarter. Over 3 fiscal years it compounded at -1.5% a year.

Context

  • Depreciation & amortization amounted to 34.7% of revenue in FY2025, up 6.9 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -16.7% toward the trailing-twelve-month pace of +36.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$12.8M-72.5% QoQ
Last fiscal yearDec 2025
$58.99M-6.4% YoY
LTMMar 2026
$89.29M+36.3% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-16.7%——
1 year-6.4%——
3-year CAGR-1.5%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
58.99M USD
Year-over-year change
-6.4%
4-year CAGR
+19.3%

Depreciation & Amortization vs competitors

How DNA compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +36.3% is the 2nd highest of 9, against a peer median of -8.7%.
  • Depreciation & amortization amounts to 63.2% of revenue for DNA, versus a peer median of 13.7%.
DNA Competitors
Depreciation & Amortization for DNA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 2026$89.29M USD+36.3%-1.5%63.2%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$56.96M USD-3.2%+16.6%27.3%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$42.96M USD-7.4%+30.8%11.3%
MGTXMeiraGTx Holdings plcLTM Mar 2026$12.82M USD+2.6%+13.6%16.1%
VIRVir Biotechnology, Inc.LTM Mar 2026$11.62M USD-10.0%+19.9%17.7%
VALNValneva SELTM Mar 2026€6.46M EUR-64.9%+1.1%4.1%
ARVNArvinas, Inc.LTM Mar 2026$4.5M USD-21.1%-14.1%5.0%
REPLReplimune Group, Inc.LTM Dec 2025$3.61M USD-34.2%+9.0%—
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$343K USD+39.4%+64.2%—
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 USD———
Peer median (excluding DNA) —-8.7%+15.1%13.7%

Competitors are the stored peer set for DNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue313.84M477.71M251.46M227.04M170.16M
Cost of Revenue129.69M204.22M54.01M38.55M31.52M
Gross Profit184.15M273.49M197.45M188.49M138.63M
Gross Margin58.7%57.3%78.5%83.0%81.5%
Research & Development1.15B1.05B580.62M424.06M243.77M
Selling, General & Admin862.95M1.43B385.03M246.16M183.29M
Operating Expenses2.01B2.48B1.06B748.25M453.91M
Depreciation & Amortization29.08M61.63M71.55M63.02M58.99M
EBITDA(1.81B)(2.06B)(821.29M)(484.39M)(254.61M)
EBITDA Margin-575.7%-431.2%-326.6%-213.3%-149.6%
Operating Income(1.83B)(2.21B)(864.41M)(559.76M)(315.28M)
Operating Margin-582.6%-462.4%-343.8%-246.5%-185.3%
Interest Income837K20.26M57.22M38.61M22.62M
Interest Expense2.37M106K93K94K0
Other Income / Expenses(9.66M)87.55M(28.53M)12.25M1.68M
Income Before Tax(1.84B)(2.12B)(892.94M)(547.51M)(313.6M)
Pre-Tax Margin-585.7%-444.1%-355.1%-241.1%-184.3%
Income Tax Expense(1.48M)(15.03M)(71K)(479K)(837K)
Net Income(1.83B)(2.1B)(892.87M)(547.03M)(312.76M)
Net Margin-583.1%-440.6%-355.1%-240.9%-183.8%
EPS (Basic)(53.83)(50.15)(18.37)(10.54)(5.64)
EPS (Diluted)(55.53)(50.20)(18.40)(10.54)(5.64)
Weighted Avg Shares32.95M41.93M48.53M51.89M55.46M
Weighted Avg Shares (Diluted)34.01M42M48.61M51.89M55.46M

Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Intrinsic Alpha fair value

Locked

Current Price

$8.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.